To the content
1 . 2025
PDF (RUS)

A meta-analysis of randomized clinical trials of the effectiveness of Riamilovir in the etiotropic therapy of acute respiratory viral infections in patients of different age groups

Abstract

Aim. Carry out a meta-analysis of randomized controlled clinical trials of the effectiveness of riamilovir (Triazavirin®) in the etiotropic therapy of acute respiratory viral infection in adults and school-age children (6–17 years old).

Material and methods. The meta-analysis was performed in accordance with the PRISMA principles for the quality of presentation of information on the results of systematic reviews and meta-analyses devoted to the evaluation of medical interventions. According to the search results in PubMed databases, eLIBRARY.ru and cyberleninka.ru at the request of «triazavirin», «riamilovir», «triazavirin», «riamilovir» and the analysis of compliance with the inclusion criteria, 4 papers were selected. As a result, the analysis included 949 patients from 31 centers with a confirmed diagnosis of acute respiratory viral infection and laboratory-confirmed absence of influenza virus antigens. The effectiveness of riamilovir (Triazavirin®, capsules 100 and 250 mg) in daily doses of 500 and 750 mg in adult patients, at a dose of 500 mg per day in adolescents aged 12–17 years and at a dose of 200 mg per day in children aged 6–11 years compared with placebo, was evaluated for 5 days of treatment.

Results. A meta-analysis confirmed a significant association between the use of riamilovir (Triazavirin®) and the chance of a sustained improvement in clinical symptoms on day 5 of treatment. Therapy with riamilovir (Triazavirin®) compared with placebo has a statistically significant difference in the proportion of patients with normalization of body temperature by the 5th day after the start of therapy, and the proportion of patients with complete disappearance of all symptoms by the end of the 5th day after the start of therapy was 6 times higher than in the Placebo group.

Conclusion. A meta-analysis of randomized multicenter, double-blind clinical trials of the efficacy and safety of etiotropic ARVI therapy in school-age children (6–17 years old) and adults showed the reliability of the established effectiveness of antiviral therapy with riamilovir (Triazavirin®) in patients, therefore, the drug can be recommended as a first-line etiotropic therapy in adult and pediatric patients with respiratory viral diseases.

Keywords: meta-analysis; riamilovir; adults; children; clinical efficacy; acute respiratory viral infection

Conflict of interest. The authors declare that they have no competing interests.

Funding. The authors declare that there is no external funding for the exploration and analysis work.

Contribution. The concept and design of the study – Gorelov A.V., Zhdanov K.V., Lioznov D.A.; collection and processing of the material – Sabitov A.U., Esaulenko E.V.; statistical processing – Esaulenko E.V., Sorokin P.V.; writing – Sabitov A.U., Esaulenko E.V., Sorokin P.V.; editing – Lobzin Yu.V., Lioznov D.A., Kozlov K.V.

For citation: Gorelov A.V., Lobzin Yu.V., Zhdanov K.V., Lioznov D.A., Kozlov K.V., Sabitov A.U., Esaulenko E.V., Sorokin P.V. A meta-analysis of randomized clinical trials of the effectiveness of Riamilovir in the etiotropic therapy of acute respiratory viral infections in patients of different age groups. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2025; 14 (1): 16-26. DOI: https://doi.org/10.33029/2305-3496-2025-14-1-16-26 (in Russian)

References

  1. Acute respiratory viral infection (ARVI). Federal Clinical Guidelines of the Ministry of Health of the Russian Federation. Moscow, 2021. URL: https://cr.minzdrav.gov.ru/view-cr/724_1 (in Russian)
  2. Kiselev O.I., Sologub T.V., Romantsov M.G. Etiopathogenetic pharmacotherapy of acute respiratory viral infections and influenza. Lechashchiy vrach [Attending Physician]. 2011; (2): 92–7. (in Russian)
  3. Karetkina G.N. Use of interferon inducers for treatment and prevention of influenza and other acute respiratory viral infections. Lechashchiy vrach [Attending Physician]. 2009; (10): 36–40 DOI: https://www.lvrach.ru/2009/10/10861672 (in Russian)
  4. Larina V.N., Zakharova M.I., Benevskaya V.F., et al. Acute respiratory viral infections and influenza: etiology, diagnosis and treatment algorithm. RMJ. Medical Review. 2019; 3 (9-1): 18–23. (in Russian)
  5. Bulgakova V.A., Poromov A.A., Grekova A.I., Pshenichnaya N.Y., Selkova E.P., Lvov N.I., et al. Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups. Terapevticheskii arkhiv [Therapeutic Archive]. 2017; 89 (1): 62–71. DOI: https://doi.org/10.17116/terarkh201789162-71 (in Russian)
  6. Sabitov A.U., Kovtun O.P., Batskalevich N.A., Maltsev O.V., Zhdanov K.V., Esaulenko E.V., et al. Meta-analysis of randomized controlled clinical trials of Riamilovir effcacy in the etiotropic therapy of acute respiratory viral infection. Antibiotiki i khimioterapiya [Antibiotics and Chemotherapy]. 2021; 66 (5–6): 48–57. DOI: https://doi.org/10.37489/0235-2990-2021-66-5-6-48-57 (in Russian)
  7. Sabitov A.U., Kovtun O.P., Batskalevich N.A., Lvov N.I., Zhdanov K.V., Esaulenko E.V., et al. Meta-analysis of randomized clinical trials of Riamilovir effcacy in etiotropic therapy of influenza. Antibiotiki i khimioterapiya [Antibiotics and Chemo­therapy]. 2021; 66 (5–6): 58–71. DOI: https://doi.org/10.37489/0235-2990-2021-66-5-6-58-71 (in Russian)
  8. Sabitov A.U., Lioznov D.A., Zhdanov K.V., Tihonova E.P., Esaulenko E.V., Sorokin P.V. Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of the drug riamilovir for the prevention of COVID-19. Terapevticheskii arkhiv [Therapeutic Archive]. 2024; 96 (3): 280–5. DOI: https://doi.org/10.26442/00403660.2024.03.202652 (in Russian)
  9. Kozlov K.V., Maltsev O.V., Kasyanenko K.V., Sukachev V.S., Saulevich A.V., Karyakin S.S., et al. Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives. Terapevticheskii arkhiv [Therapeutic Archive]. 2024; 96 (11): 1035–41. DOI: https://doi.org/10.26442/00403660.2024.11.203024 (in Russian)
  10. Sabitov AU, Kovtun OP, Esaulenko EV, Sorokin PV. A new approach to etiotropic therapy ARVI in children. Terapevticheskii arkhiv [Therapeutic Archive]. 2022; 94 (11): 1278–84. DOI: https://doi.org/10.26442/00403660.2022.11.201979 (in Russian)
  11. Zhdanov K.V., Lobzin Yu.V., Sabitov A.U., Esaulenko E.V., Sorokin P.V. Prospects for expanding the possibilities of etiotropic therapy of acute respiratory viral infections in children of primary school age. Antibiotiki i khimioterapiya [Antibiotics and Chemotherapy]. 2025; 70 (1–2): 29–36. (in Russian)
  12. Gorelov A.V., Zhdanov K.V., Lobzin Yu.V., Sabitov A.U., Lioznov D.A., Esaulen-ko E.V., Sorokin P.V. Meta-analysis of randomized clinical trials on the efficacy of Riamilovir in the etiotropic treatment of acute respiratory viral infections in school-age children. Infekc. bolezni [Infectious Diseases]. 2025; 23 (1): 73–84. DOI: https://doi.org/10.20953/1729-9225-2025-1-73-84 (in Russian)
  13. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 2021; 18 (3): e1003583. DOI: https://doi.org/10.1371/journal.pmed.1003583
  14. Tokin I.I., Zubkova T.G., Drozdova Yu.V., Lioznov D.A. Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug. Infekc bolezni [Infectious Diseases]. 2019; 17 (4): 13–7. DOI: https://doi.org/10.20953/1729-9225-2019-4-13-17 (in Russian)
  15. Lioznov D.A., Tokin I.I., Zubkova T.G., Sorokin P.V. The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection. Terapevticheskii arkhiv [Therapeutic Archive]. 2020; 92 (12): 160-4. DOI: https://doi.org/10.26442/00403660.2020.12.200427 (in Russian)
  16. Omelyanovsky V.V., Avksentyeva M.V., Sura M.V., et al. Methodological recommendations for assessing the quality of statistical analysis in clinical trials. Moscow: Center for Expertise and Quality Control of Medical Care of the Ministry of Health of the Russian Federation, 2017. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)
geotar-digit
Journals of «GEOTAR-Media»